682 related articles for article (PubMed ID: 15519006)
1. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
2. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
4. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
Koren MJ
Am J Med; 2005 Dec; 118 Suppl 12A():16-21. PubMed ID: 16356803
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
8. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
9. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
10. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
17. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
[TBL] [Abstract][Full Text] [Related]
19. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
20. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]